Biosimilars: Timing, Marketing Considerations For Suffix Selection In The US
This article was originally published in SRA
Executive Summary
It may be years before the US Food and Drug Administration officially begins implementing its proposal to add a suffix to the nonproprietary names of biologics that already are approved.